Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
REBEL: Ranibizumab vs Bevacizumab in DME
NCT04991350Phase 4Terminated
- Sponsor
- Cairo University
- Start
- Nov 2021
- Primary completion
- Sep 2022
- Modality
- Antibody Fragments, Antibody Conjugates, Monoclonal Antibodies
- Countries
- 1
01
Overview
A Phase 4 trial of ranibizumab, bevacizumab in diabetic macular edema (DME), sponsored by Cairo University. Started Nov 2021; status: terminated.
02
Drugs
ranibizumabbevacizumab
03
Conditions
diabetic macular edema (DME)
Beyond the preview
Go deeper on NCT04991350.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT04991350.